

Announcement Summary

## **Entity name**

KAZIA THERAPEUTICS LIMITED

## Announcement Type

New announcement

# Date of this announcement

Wednesday September 21, 2022

#### The +securities to be quoted are: ☑ Other

Total number of +securities to be quoted

ASX +s	ecurity	Number of +securities to	Issue date
code	Security description	be quoted	
KZA	ORDINARY FULLY PAID	60,000	14/09/2022

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

## 1.1 Name of entity

KAZIA THERAPEUTICS LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

**1.2 Registered number type** ABN Registration number 37063259754

1.3 ASX issuer code KZA

1.4 The announcement is

Solution New announcement

#### 1.5 Date of this announcement

21/9/2022



# Part 2 - Type of Issue

2.1 The +securities to be quoted are:

C Other

## 2.2 The +securities to be quoted are:

C Additional +securities in a class that is already quoted on ASX ("existing class")

2.3c Have these +securities been offered under a +disclosure document or +PDS? No

2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B

These securities were issued to members of the Scientific Advisory Board for services rendered, in lieu of fees.



Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an

Appendix 3B

## Additional +securities to be quoted in an existing class

ASX +security code and description KZA : ORDINARY FULLY PAID

#### Issue date

14/9/2022

Issue details

Number of +securities to be quoted 60,000

Are the +securities being issued for a cash consideration?

🕑 No

#### Please describe the consideration being provided for the +securities

Issued to members of the former Scientific Advisory Board for services rendered.

# Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted

0.210000

#### Any other information the entity wishes to provide about the +securities to be quoted

#### The purpose(s) for which the entity is issuing the securities

To pay for services rendered

#### Please provide additional details

Issued to members of the former Scientific Advisory Board for services rendered.



Part 4 - Issued capital following quotation

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)

ASX +security code and description	Total number of +securities on issue
KZA : ORDINARY FULLY PAID	150,376,036

4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
KZAAG : OPTION EXPIRING 04-JAN-2025 EX \$1.69	200,000
KZAAF : OPTION EXPIRING 09-NOV-2024 EX \$1.132	1,200,000
KZAAD : OPTION EXPIRING 13-NOV-2023 EX \$0.4925	1,200,000
KZAAB : OPTION EXPIRING 09-NOV-2024 EX \$0.8812	800,000
KZAAE : OPTION EXPIRING 13-JAN-2025 EX \$0.8812	200,000
KZAAA : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	240,000
KZAAN : OPTION EXPIRING 16-NOV-2025 EX \$1.69	1,000,000
KZAAO : OPTION EXPIRING 16-NOV-2025 EX \$2.24	1,500,000
KZAAP : OPTION EXPIRING 16-NOV-2026 EX \$1.56	800,000
KZAAR : OPTION EXPIRING 24-MAY-2027 EX \$0.78	100,000
KZAAQ : OPTION EXPIRING 01-FEB-2027 EX \$0.94	1,300,000
KZAAH : OPTION EXPIRING 21-JUN-2026 EX \$1.365	100,000



# Part 5 - Other Listing Rule requirements

5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1? ☑ No

5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

60000

5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)? ⓒ No